[go: up one dir, main page]

CA3173845A1 - Utilisation d'administration d'inhibiteurs de nf-kb a partir d'exosomes - Google Patents

Utilisation d'administration d'inhibiteurs de nf-kb a partir d'exosomes Download PDF

Info

Publication number
CA3173845A1
CA3173845A1 CA3173845A CA3173845A CA3173845A1 CA 3173845 A1 CA3173845 A1 CA 3173845A1 CA 3173845 A CA3173845 A CA 3173845A CA 3173845 A CA3173845 A CA 3173845A CA 3173845 A1 CA3173845 A1 CA 3173845A1
Authority
CA
Canada
Prior art keywords
exo
inhibitor
exosome
photo
specific binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173845A
Other languages
English (en)
Inventor
Chulhee Choi
Kyungsun CHOI
Jae-Kwang YOO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilias Biologics Inc
Original Assignee
Ilias Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilias Biologics Inc filed Critical Ilias Biologics Inc
Publication of CA3173845A1 publication Critical patent/CA3173845A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés de traitement d'insuffisance rénale aiguë qui utilisent des exosomes contenant des inhibiteurs NF-?B. La présente invention concerne des méthodes de traitement de maladies induites par sepsis à l'aide d'exosomes contenant un inhibiteur NF-?B.
CA3173845A 2020-03-31 2021-03-31 Utilisation d'administration d'inhibiteurs de nf-kb a partir d'exosomes Pending CA3173845A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR20200039011 2020-03-31
KR10-2020-0039011 2020-03-31
US202063112154P 2020-11-10 2020-11-10
US63/112,154 2020-11-10
US202063112155P 2020-11-11 2020-11-11
US63/112,155 2020-11-11
PCT/IB2021/052708 WO2021198961A1 (fr) 2020-03-31 2021-03-31 Utilisation d'administration d'inhibiteurs de nf-kb à partir d'exosomes

Publications (1)

Publication Number Publication Date
CA3173845A1 true CA3173845A1 (fr) 2021-10-07

Family

ID=77928093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173845A Pending CA3173845A1 (fr) 2020-03-31 2021-03-31 Utilisation d'administration d'inhibiteurs de nf-kb a partir d'exosomes

Country Status (7)

Country Link
EP (1) EP4127136A4 (fr)
JP (1) JP7498293B2 (fr)
KR (2) KR102852789B1 (fr)
CN (1) CN115335079A (fr)
AU (1) AU2021247253B2 (fr)
CA (1) CA3173845A1 (fr)
WO (1) WO2021198961A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115212234B (zh) * 2021-10-22 2023-11-10 武汉大学中南医院 纤维网状细胞来源的外泌体在制备用于治疗和/或预防脓毒症急性肾损伤的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2983721T (pt) * 2013-04-12 2018-03-13 Evox Therapeutics Ltd Vesículas de entrega terapêutica
KR101877010B1 (ko) * 2016-09-30 2018-08-09 한국과학기술원 super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
JP2019528674A (ja) * 2016-09-30 2019-10-17 セレックス ライフ サイエンシズ，インコーポレーテッド タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法
EP3548005A4 (fr) * 2016-11-29 2020-06-17 Puretech Health LLC Exosomes destinés à l'administration d'agents thérapeutiques
CN107158390A (zh) * 2017-07-12 2017-09-15 上海市东方医院 组蛋白去乙酰化酶hdac6的抑制剂在制备防治急性肾损伤药物中的用途

Also Published As

Publication number Publication date
KR20210124180A (ko) 2021-10-14
KR20220149781A (ko) 2022-11-08
AU2021247253B2 (en) 2024-10-31
WO2021198961A1 (fr) 2021-10-07
JP2023519700A (ja) 2023-05-12
EP4127136A1 (fr) 2023-02-08
KR102852789B1 (ko) 2025-09-01
JP7498293B2 (ja) 2024-06-11
EP4127136A4 (fr) 2024-04-03
AU2021247253A1 (en) 2022-10-20
CN115335079A (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
JP7275193B2 (ja) 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
Tang et al. Modified chitosan for effective renal delivery of siRNA to treat acute kidney injury
CN113694075A (zh) 用于医治疾病的外泌体的用途
US11779600B2 (en) Methods of treating or preventing alzheimer's disease and associated conditions
Liu et al. ATG2B upregulated in LPS-stimulated BMSCs-derived exosomes attenuates septic liver injury by inhibiting macrophage STING signaling
AU2021247253B2 (en) Use of exosome-based delivery of NF-κB inhibitors
US12472228B2 (en) Use of exosome-based delivery of NF-κB inhibitors
WO2014066122A1 (fr) Traitement de tumeurs à l'aide de cellules souches mésenchymateuses activées
US20250144034A1 (en) Modified extracellular vesicles that specifically target kidneys and methods of preparation and applications thereof
Sun et al. FcRn-targeting and ROS-responsive Fedratinib-incorporated nanoparticles alleviate asthma by inducing eosinophil apoptosis
KR20230159847A (ko) 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법
Yue et al. IsoalloLCA-intervened regulatory T cell exosomes alleviate inflammatory bowel disease by inhibiting NF-κB-associated inflammation in intestinal epithelial cells
JP2018524287A (ja) 造影後の膵炎のリスクを低下させるための組成物及び方法
Ko et al. Metabolic Click-labeling of Interleukin-10 Enhances Immunomodulatory Potential and Wound Healing Properties of Mesenchymal Stem Cell-derived Extracellular Nanovesicles
ES2993108T3 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
WO2023183855A1 (fr) Procédés d'administration utilisant des plaquettes
ES2843724T3 (es) Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral
WO2019146805A1 (fr) Agent thérapeutique contre la dégénérescence lobaire fronto-temporale, procédé de criblage d'agents thérapeutiques contre la dégénérescence lobaire fronto-temporale et méthode de traitement de la dégénérescence lobaire fronto-temporale
Zhu et al. The delivery of PD-L1 siRNA by neutrophil-targeted lipid nanoparticles effectively ameliorates sepsis
US20220202955A1 (en) Composition and method for inhibiting tau protein accumulation, aggregation, and tangle formation
Sekar et al. Therapeutic potential of red blood cell-derived extracellular vesicles in reducing neuroinflammation and protecting against retinal degeneration
US20250195661A1 (en) NIR-responsive stem cell-derived inflammation attenuating complex and use thereof
US20250177573A1 (en) Materials & Methods for Treatment of Macular Degeneration
US20250255976A1 (en) Cationic biomaterials ameliorate obesity-associated chronic inflammation and focal adiposity
Colomer et al. Astrocyte CB1 receptors drive blood-brain barrier disruption in CNS inflammatory disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928